The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer.
Humans
Female
Genetic Predisposition to Disease
Breast Neoplasms
/ genetics
Ovarian Neoplasms
/ genetics
Hormone Replacement Therapy
/ adverse effects
Genital Neoplasms, Female
/ genetics
Heterozygote
Hereditary Breast and Ovarian Cancer Syndrome
/ genetics
Germany
BRCA2 Protein
/ genetics
BRCA1 Protein
/ genetics
BRCA1 and BRCA2
Breast cancer
Fertility treatment
Hormone therapy
Oral contraception
Ovarian cancer
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
11 Sep 2024
11 Sep 2024
Historique:
received:
31
07
2024
accepted:
30
08
2024
medline:
11
9
2024
pubmed:
11
9
2024
entrez:
11
9
2024
Statut:
epublish
Résumé
To support doctors in counselling women with genetic predisposition for breast or gynecologic cancers on endocrine interventions. Evidence on the safety of endocrine interventions for fertility treatment, contraception, hormone replacement therapy after risk-reducing salpingo-oophorectomy (RRSO) or treatment of symptoms during peri- and postmenopause was analysed for carriers of probably pathogenic and pathogenic variants in BRCA1 or BRCA2 (BRCA1/2-pV), in other breast and ovarian cancer genes and the Lynch Syndrome. Cancer risks were compared with data on risks for the general population. Data on risk modulation of endocrine interventions in women with genetic predisposition is limited. Ovarian hyperstimulation for fertility treatment may be performed. Oral contraceptives should not be used to reduce ovarian cancer risk in BRCA1/2-pV carriers. Premenopausal BRCA1/2-pV carriers and carriers of pV in Lynch Syndrome genes should be offered hormone replacement therapy (HRT) after RRSO, to prevent diseases caused by estrogen deficiency. Effect direction and strength of risk modulation by endocrine interventions is similar to the general population. Participation of individuals at risk in prospective registries is recommended.
Identifiants
pubmed: 39259360
doi: 10.1007/s00432-024-05936-7
pii: 10.1007/s00432-024-05936-7
doi:
Substances chimiques
BRCA2 Protein
0
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
417Investigateurs
T Fehm
(T)
A Hahne
(A)
D Huber
(D)
E Kühnle
(E)
K Mohr
(K)
K Rhiem
(K)
S Seitz
(S)
D Speiser
(D)
Informations de copyright
© 2024. The Author(s).
Références
Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SAA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O’Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712. https://doi.org/10.1001/jama.291.14.1701
doi: 10.1001/jama.291.14.1701
pubmed: 15082697
Bakken K, Alsaker E, Eggen AE, Lund E (2004) Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer 112:130–134. https://doi.org/10.1002/ijc.20389
doi: 10.1002/ijc.20389
pubmed: 15305384
Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, Fabre A, Hémon B, Rinaldi S, Chajes V, Slimani N, Allen NE, Reeves GK, Bingham S, Khaw K-T, Olsen A, Tjønneland A, Rodriguez L, Sánchez M-J, Etxezarreta PA, Ardanaz E, Tormo M-J, Peeters PH, van Gils CH, Steffen A, Schulz M, Chang-Claude J, Kaaks R, Tumino R, Gallo V, Norat T, Riboli E, Panico S, Masala G, González CA, Berrino F (2011) Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 128:144–156. https://doi.org/10.1002/ijc.25314
doi: 10.1002/ijc.25314
pubmed: 20232395
Barcroft JF, Galazis N, Jones BP, Getreu N, Bracewell-Milnes T, Grewal KJ, Sorbi F, Yazbek J, Lathouras K, Smith JR, Hardiman P, Thum M-Y, Ben-Nagi J, Ghaem-Maghami S, Verbakel J, Saso S (2021) Fertility treatment and cancers-the eternal conundrum: a systematic review and meta-analysis. Hum Reprod 36:1093–1107. https://doi.org/10.1093/humrep/deaa293
doi: 10.1093/humrep/deaa293
pubmed: 33586777
Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427. https://doi.org/10.1016/s0140-6736(03)14065-2
doi: 10.1016/s0140-6736(03)14065-2
pubmed: 12927427
Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371:303–314. https://doi.org/10.1016/S0140-6736(08)60167-1
doi: 10.1016/S0140-6736(08)60167-1
pubmed: 18294997
Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385:1835–1842. https://doi.org/10.1016/s0140-6736(14)61687-1
doi: 10.1016/s0140-6736(14)61687-1
pubmed: 25684585
Challberg J, Ashcroft L, Lalloo F, Eckersley B, Clayton R, Hopwood P, Selby P, Howell A, Evans DG (2011) Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. Br J Cancer 105:22–27. https://doi.org/10.1038/bjc.2011.202
doi: 10.1038/bjc.2011.202
pubmed: 21654687
pmcid: 3137416
Cherry N, Gilmour K, Hannaford P, Heagerty A, Khan MA, Kitchener H, McNamee R, Elstein M, Kay C, Seif M, Buckley H (2002) Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 360:2001–2008. https://doi.org/10.1016/s0140-6736(02)12001-0
doi: 10.1016/s0140-6736(02)12001-0
pubmed: 12504395
Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, Barrington W, Kuller LH, Simon MS, Lane D, Johnson KC, Rohan TE, Gass MLS, Cauley JA, Paskett ED, Sattari M, Prentice RL (2020) Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. JAMA 324:369–380. https://doi.org/10.1001/jama.2020.9482
doi: 10.1001/jama.2020.9482
pubmed: 32721007
pmcid: 7388026
Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, Zikan M, Dusek L (2010) Hormonal contraception and risk of cancer. Hum Reprod Update 16:631–650. https://doi.org/10.1093/humupd/dmq022
doi: 10.1093/humupd/dmq022
pubmed: 20543200
Cibula D, Zikan M, Dusek L, Majek O (2011) Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther 11:1197–1207. https://doi.org/10.1586/era.11.38
doi: 10.1586/era.11.38
pubmed: 21916573
Clendenen TV, Kim S, Moy L, Wan L, Rusinek H, Stanczyk FZ, Pike MC, Zeleniuch-Jacquotte A (2013) Magnetic resonance imaging (MRI) of hormone-induced breast changes in young premenopausal women. Magn Reson Imaging 31:1–9. https://doi.org/10.1016/j.mri.2012.06.022
doi: 10.1016/j.mri.2012.06.022
pubmed: 22898693
Colditz GA, Stampfer MJ, Willett WC, Hunter DJ, Manson JE, Hennekens CH, Rosner BA, Speizer FE (1992) Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses’ Health Study. Cancer Causes Control 3:433–439. https://doi.org/10.1007/BF00051356
doi: 10.1007/BF00051356
pubmed: 1525324
Collaborative Group on Hormonal Factors in Breast Cancer (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394:1159–1168. https://doi.org/10.1016/S0140-6736(19)31709-X
doi: 10.1016/S0140-6736(19)31709-X
pmcid: 6891893
Collaborative Group on Hormonal Factors in Breast Cancer, van den Brandt PA, Goldbohm RA (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713–1727. https://doi.org/10.1016/s0140-6736(96)90806-5
doi: 10.1016/s0140-6736(96)90806-5
de Jonge MM, Mooyaart AL, Vreeswijk MPG, de Kroon CD, van Wezel T, van Asperen CJ, Smit VTHBM, Dekkers OM, Bosse T (2017) Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: a meta-analysis and case report. Eur J Cancer 72:215–225. https://doi.org/10.1016/j.ejca.2016.11.028
doi: 10.1016/j.ejca.2016.11.028
pubmed: 28049106
Dominguez-Valentin M, Sampson JR, Seppälä TT, ten Broeke SW, Plazzer J-P, Nakken S, Engel C, Aretz S, Jenkins MA, Sunde L, Bernstein I, Capella G, Balaguer F, Thomas H, Evans DG, Burn J, Greenblatt M, Hovig E, de Vos Tot Nederveen Cappel WH, Sijmons RH, Bertario L, Tibiletti MG, Cavestro GM, Lindblom A, Della Valle A, Lopez-Köstner F, Gluck N, Katz LH, Heinimann K, Vaccaro CA, Büttner R, Görgens H, Holinski-Feder E, Morak M, Holzapfel S, Hüneburg R, von Knebel Doeberitz M, Loeffler M, Rahner N, Schackert HK, Steinke-Lange V, Schmiegel W, Vangala D, Pylvänäinen K, Renkonen-Sinisalo L, Hopper JL, Win AK, Haile RW, Lindor NM, Gallinger S, Le Marchand L, Newcomb PA, Figueiredo JC, Thibodeau SN, Wadt K, Therkildsen C, Okkels H, Ketabi Z, Moreira L, Sánchez A, Serra-Burriel M, Pineda M, Navarro M, Blanco I, Green K, Lalloo F, Crosbie EJ, Hill J, Denton OG, Frayling IM, Rødland EA, Vasen H, Mints M, Neffa F, Esperon P, Alvarez K, Kariv R, Rosner G, Pinero TA, Gonzalez ML, Kalfayan P, Tjandra D, Winship IM, Macrae F, Möslein G, Mecklin J-P, Nielsen M, Møller P (2020) Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the prospective Lynch syndrome database. Genet Med 22:15–25. https://doi.org/10.1038/s41436-019-0596-9
doi: 10.1038/s41436-019-0596-9
pubmed: 31337882
Dominick S, Hickey M, Chin J, Su HI (2015) Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007245.pub3
doi: 10.1002/14651858.CD007245.pub3
pubmed: 26649916
pmcid: 6823262
Faubion SS, Kuhle CL, Shuster LT, Rocca WA (2015) Long-term health consequences of premature or early menopause and considerations for management. Climacteric 18:483–491. https://doi.org/10.3109/13697137.2015.1020484
doi: 10.3109/13697137.2015.1020484
pubmed: 25845383
pmcid: 4581591
Fitzpatrick D, Pirie K, Reeves G, Green J, Beral V (2023) Combined and progestagen-only hormonal contraceptives and breast cancer risk: a UK nested case-control study and meta-analysis. PLoS Med 20:e1004188. https://doi.org/10.1371/journal.pmed.1004188
doi: 10.1371/journal.pmed.1004188
pubmed: 36943819
pmcid: 10030023
Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114:448–454. https://doi.org/10.1002/ijc.20710
doi: 10.1002/ijc.20710
pubmed: 15551359
Fournier A, Berrino F, Clavel-Chapelon F (2008) Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107:103–111. https://doi.org/10.1007/s10549-007-9523-x
doi: 10.1007/s10549-007-9523-x
pubmed: 17333341
Gaba F, Manchanda R (2020) Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers. Best Pract Res Clin Obstet Gynaecol 65:46–65. https://doi.org/10.1016/j.bpobgyn.2020.01.006
doi: 10.1016/j.bpobgyn.2020.01.006
pubmed: 32192936
Gabrielson M, Azam S, Hardell E, Holm M, Ubhayasekera KA, Eriksson M, Bäcklund M, Bergquist J, Czene K, Hall P (2020) Hormonal determinants of mammographic density and density change. Breast Cancer Res 22:95. https://doi.org/10.1186/s13058-020-01332-4
doi: 10.1186/s13058-020-01332-4
pubmed: 32847607
pmcid: 7449090
Georgakis MK, Beskou-Kontou T, Theodoridis I, Skalkidou A, Petridou ET (2019) Surgical menopause in association with cognitive function and risk of dementia: a systematic review and meta-analysis. Psychoneuroendocrinology 106:9–19. https://doi.org/10.1016/j.psyneuen.2019.03.013
doi: 10.1016/j.psyneuen.2019.03.013
pubmed: 30928686
Gronwald J, Glass K, Rosen B, Karlan B, Tung N, Neuhausen SL, Moller P, Ainsworth P, Sun P, Narod SA, Lubinski J, Kotsopoulos J (2016) Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertil Steril 105:781–785. https://doi.org/10.1016/j.fertnstert.2015.11.034
doi: 10.1016/j.fertnstert.2015.11.034
pubmed: 26698676
Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ (2010) Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral Contraception Study. BMJ 340:c927. https://doi.org/10.1136/bmj.c927
doi: 10.1136/bmj.c927
pubmed: 20223876
pmcid: 2837145
Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu Cr CR, Liu Ch CH, Azen SP (2001) Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 135:939–953. https://doi.org/10.7326/0003-4819-135-11-200112040-00005
doi: 10.7326/0003-4819-135-11-200112040-00005
pubmed: 11730394
Huber D, Seitz S, Kast K, Emons G, Ortmann O (2020a) Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet 302:715–720. https://doi.org/10.1007/s00404-020-05690-4
doi: 10.1007/s00404-020-05690-4
pubmed: 32719921
pmcid: 7447664
Huber D, Seitz S, Kast K, Emons G, Ortmann O (2020b) Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet 301:875–884. https://doi.org/10.1007/s00404-020-05458-w
doi: 10.1007/s00404-020-05458-w
pubmed: 32140806
pmcid: 8494665
Huber D, Seitz S, Kast K, Emons G, Ortmann O (2021) Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review. J Cancer Res Clin Oncol 147:2035–2045. https://doi.org/10.1007/s00432-021-03629-z
doi: 10.1007/s00432-021-03629-z
pubmed: 33885953
pmcid: 8164576
Jensen A, Sharif H, Frederiksen K, Kjaer SK (2009) Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. BMJ 338:b249. https://doi.org/10.1136/bmj.b249
doi: 10.1136/bmj.b249
pubmed: 19196744
pmcid: 2640154
Kessous R, Davidson E, Meirovitz M, Sergienko R, Sheiner E (2016) The risk of female malignancies after fertility treatments: a cohort study with 25-year follow-up. J Cancer Res Clin Oncol 142:287–293. https://doi.org/10.1007/s00432-015-2035-x
doi: 10.1007/s00432-015-2035-x
pubmed: 26337160
Kim J, Turan V, Oktay K (2016) Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab 101:1364–1371. https://doi.org/10.1210/jc.2015-3878
doi: 10.1210/jc.2015-3878
pubmed: 26751194
pmcid: 4880171
Kotsopoulos J, Lubinski J, Neuhausen SL, Lynch HT, Rosen B, Ainsworth P, Moller P, Ghadirian P, Isaacs C, Karlan B, Sun P, Narod SA (2006) Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 100:83–88. https://doi.org/10.1016/j.ygyno.2005.07.110
doi: 10.1016/j.ygyno.2005.07.110
pubmed: 16137751
Kotsopoulos J, Librach CL, Lubinski J, Gronwald J, Kim-Sing C, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Randall S, Manoukian S, Pasini B, Tung N, Ainsworth PJ, Cummings S, Sun P, Narod SA (2008) Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. Cancer Causes Control 19:1111–1119. https://doi.org/10.1007/s10552-008-9175-0
doi: 10.1007/s10552-008-9175-0
pubmed: 18509731
Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, Senter L, Demsky R, Foulkes WD, Eng C, Karlan B, Tung N, Singer CF, Sun P, Lubinski J, Narod SA (2016) Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. Breast Cancer Res Treat 155:365–373. https://doi.org/10.1007/s10549-016-3685-3
doi: 10.1007/s10549-016-3685-3
pubmed: 26780555
Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA (2018) Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA Oncol 4:1059–1065. https://doi.org/10.1001/jamaoncol.2018.0211
doi: 10.1001/jamaoncol.2018.0211
pubmed: 29710224
pmcid: 6143051
Laitman Y, Michaelson-Cohen R, Levi E, Chen-Shtoyerman R, Reish O, Josefsberg Ben-Yehoshua S, Bernstein-Molho R, Keinan-Boker L, Rosengarten O, Silverman BG, Perri T, Korach J, Mor P, Ephrat Ben-Baruch N, Levy Lahad E, Friedman E (2019) Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers. Cancer 125:698–703. https://doi.org/10.1002/cncr.31842
doi: 10.1002/cncr.31842
pubmed: 30489631
Lando JF, Heck KE, Brett KM (1999) Hormone replacement therapy and breast cancer risk in a nationally representative cohort. Am J Prev Med 17:176–180. https://doi.org/10.1016/s0749-3797(99)00078-1
doi: 10.1016/s0749-3797(99)00078-1
pubmed: 10987632
Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S, Babb de Villiers C, Izquierdo A, Simard J, Schmidt MK, Walter FM, Chatterjee N, Garcia-Closas M, Tischkowitz M, Pharoah P, Easton DF, Antoniou AC (2019) BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med 21:1708–1718. https://doi.org/10.1038/s41436-018-0406-9
doi: 10.1038/s41436-018-0406-9
pubmed: 30643217
pmcid: 6687499
Liu X, Yue J, Pervaiz R, Zhang H, Wang L (2022) Association between fertility treatments and breast cancer risk in women with a family history or BRCA mutations: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 13:986477. https://doi.org/10.3389/fendo.2022.986477
doi: 10.3389/fendo.2022.986477
pubmed: 36176466
Liu J, Jin X, Liu W, Chen W, Wang L, Feng Z, Huang J (2023) The risk of long-term cardiometabolic disease in women with premature or early menopause: a systematic review and meta-analysis. Front Cardiovasc Med 10:1131251. https://doi.org/10.3389/fcvm.2023.1131251
doi: 10.3389/fcvm.2023.1131251
pubmed: 37025693
pmcid: 10072266
Lund E, Bakken K, Dumeaux V, Andersen V, Kumle M (2007) Hormone replacement therapy and breast cancer in former users of oral contraceptives–The Norwegian Women and Cancer study. Int J Cancer 121:645–648. https://doi.org/10.1002/ijc.22699
doi: 10.1002/ijc.22699
pubmed: 17372914
Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, Goodman MT (2008) Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology 19:237–243. https://doi.org/10.1097/EDE.0b013e31816334c5
doi: 10.1097/EDE.0b013e31816334c5
pubmed: 18223481
Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O’Sullivan MJ, Powell LH, Simon MS, van Horn L, Vitolins MZ, Wallace RB (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 310:1353–1368. https://doi.org/10.1001/jama.2013.278040
doi: 10.1001/jama.2013.278040
pubmed: 24084921
Marchetti C, de Felice F, Boccia S, Sassu C, Di Donato V, Perniola G, Palaia I, Monti M, Muzii L, Tombolini V, Benedetti Panici P (2018) Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Crit Rev Oncol Hematol 132:111–115. https://doi.org/10.1016/j.critrevonc.2018.09.018
doi: 10.1016/j.critrevonc.2018.09.018
pubmed: 30447915
McCormack VA, dos Santos SI (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15:1159–1169. https://doi.org/10.1158/1055-9965.EPI-06-0034
doi: 10.1158/1055-9965.EPI-06-0034
pubmed: 16775176
Michaelson-Cohen R, Gabizon-Peretz S, Armon S, Srebnik-Moshe N, Mor P, Tomer A, Levy-Lahad E, Paluch-Shimon S (2021) Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy. Eur J Cancer 148:95–102. https://doi.org/10.1016/j.ejca.2021.02.007
doi: 10.1016/j.ejca.2021.02.007
pubmed: 33743487
Moorman PG, Calingaert B, Palmieri RT, Iversen ES, Bentley RC, Halabi S, Berchuck A, Schildkraut JM (2008) Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol 167:1059–1069. https://doi.org/10.1093/aje/kwn006
doi: 10.1093/aje/kwn006
pubmed: 18303003
Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER (2013) Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 31:4188–4198. https://doi.org/10.1200/JCO.2013.48.9021
doi: 10.1200/JCO.2013.48.9021
pubmed: 24145348
Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø (2017) Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 377:2228–2239. https://doi.org/10.1056/NEJMoa1700732
doi: 10.1056/NEJMoa1700732
pubmed: 29211679
Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O (2018) Contemporary hormonal contraception and the risk of breast cancer. ESPE. https://doi.org/10.1530/ey.15.15.9
doi: 10.1530/ey.15.15.9
Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Berek JS, Hankinson S, Manson JE (2009) Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstet Gynecol 113:1027–1037. https://doi.org/10.1097/AOG.0b013e3181a11c64
doi: 10.1097/AOG.0b013e3181a11c64
pubmed: 19384117
pmcid: 3791619
Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, Berek JS, Manson JE (2013) Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 121:709–716. https://doi.org/10.1097/AOG.0b013e3182864350
doi: 10.1097/AOG.0b013e3182864350
pubmed: 23635669
pmcid: 4254662
Perri T, Lifshitz D, Sadetzki S, Oberman B, Meirow D, Ben-Baruch G, Friedman E, Korach J (2015) Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. Fertil Steril 103:1305–1312. https://doi.org/10.1016/j.fertnstert.2015.02.011
doi: 10.1016/j.fertnstert.2015.02.011
pubmed: 25792249
Perri T, Naor-Revel S, Eliassi-Revivo P, Lifshitz D, Friedman E, Korach J (2021) Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers. Fertil Steril 116(2):538–545. https://doi.org/10.1016/j.fertnstert.2021.02.030
doi: 10.1016/j.fertnstert.2021.02.030
pubmed: 33823990
Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE (2009) Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 170:12–23. https://doi.org/10.1093/aje/kwp115
doi: 10.1093/aje/kwp115
pubmed: 19468079
pmcid: 2733042
Prentice RL, Aragaki AK, Chlebowski RT, Rossouw JE, Anderson GL, Stefanick ML, Wactawski-Wende J, Kuller LH, Wallace R, Johnson KC, Shadyab AH, Gass M, Manson JE (2021) Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50–59 years of age. Am J Epidemiol 190:365–375. https://doi.org/10.1093/aje/kwaa210
doi: 10.1093/aje/kwaa210
pubmed: 33025002
Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van Veer ‘t L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23:7804–7810. https://doi.org/10.1200/JCO.2004.00.8151
doi: 10.1200/JCO.2004.00.8151
pubmed: 16219936
Rizzuto I, Behrens RF, Smith LA (2019) Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev. 6:CD008215. https://doi.org/10.1002/14651858.CD008215.pub3
doi: 10.1002/14651858.CD008215.pub3
pubmed: 31207666
Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ (2006) Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 7:821–828. https://doi.org/10.1016/S1470-2045(06)70869-5
doi: 10.1016/S1470-2045(06)70869-5
pubmed: 17012044
SS3-Guideline “Diagnosis, Treatment and Follow-up of malignant Ovarian Tumors”: AWMF-Registrynumber: 032/035, long version. https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/LL_Ovarialkarzinom_Langversion_5.1.pdf . Accessed 26 March 2024
S3-Guideline “Endometrial Cancer”: AWMF-Registrynumber 032/034-OL, long version 2.0, September 2022. https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Endometriumkarzinom/Version_2/LL_Endometriumkarzinom_Langversion_2.0.pdf . Accessed 3 May 2024
S3-Guideline “Hormonal Contraception”: AWMF-Registrynumber 015/015, September 2020, Version 1.2. https://register.awmf.org/assets/guidelines/015-015l_S3_Hormonelle_Empfaengnisverhuetung_2020-09.pdf . Accessed 3 May 2024
S3-Guideline “Peri- and Postmenopause—Diagnosis and Interventions: Guideline of the German Society of Gynecology and Obstetrics (S-3 Level, AWMF Registry No. 015–062); October 2018. http://www.awmf.org/leitlinien/detail/ll/015-062.html . Accessed 27 November 2021
S3-Guideline “Screening, Diagnosis, Treatment and Follow-up of Breast Cancer”: AWMF-Registrynumber: 032–045, long version, Version 4.4, June 2021. https://register.awmf.org/assets/guidelines/032-045OLl_S3_Mammakarzinom_2021-07.pdf . Accessed 26.03.24
Saxena T, Lee E, Henderson KD, Clarke CA, West D, Marshall SF, Deapen D, Bernstein L, Ursin G (2010) Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiol Biomarkers Prev 19:2366–2378. https://doi.org/10.1158/1055-9965.EPI-10-0162
doi: 10.1158/1055-9965.EPI-10-0162
pubmed: 20699377
pmcid: 2936672
Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485–491. https://doi.org/10.1001/jama.283.4.485
doi: 10.1001/jama.283.4.485
pubmed: 10659874
Schrijver LH, Olsson H, Phillips K-A, Terry MB, Goldgar DE, Kast K, Engel C, Mooij TM, Adlard J, Barrowdale D, Davidson R, Eeles R, Ellis S, Evans DG, Frost D, Izatt L, Porteous ME, Side LE, Walker L, Berthet P, Bonadona V, Leroux D, Mouret-Fourme E, Venat-Bouvet L, Buys SS, Southey MC, John EM, Chung WK, Daly MB, Bane A, van Asperen CJ, Gómez Garcia EB, Mourits MJE, van Os TAM, Roos-Blom M-J, Friedlander ML, McLachlan S-A, Singer CF, Tan YY, Foretova L, Navratilova M, Gerdes A-M, Caldes T, Simard J, Olah E, Jakubowska A, Arver B, Osorio A, Noguès C, Andrieu N, Easton DF, van Leeuwen FE, Hopper JL, Milne RL, Antoniou AC, Rookus MA (2018) Oral contraceptive use and breast cancer risk: retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study. JNCI Cancer Spectr. 2:023. https://doi.org/10.1093/jncics/pky023
doi: 10.1093/jncics/pky023
Schrijver LH, Antoniou AC, Olsson H, Mooij TM, Roos-Blom M-J, Azarang L, Adlard J, Ahmed M, Barrowdale D, Davidson R, Donaldson A, Eeles R, Evans DG, Frost D, Henderson A, Izatt L, Ong K-R, Bonadona V, Coupier I, Faivre L, Fricker J-P, Gesta P, van Engelen K, Jager A, Menko FH, Mourits MJE, Singer CF, Tan YY, Foretova L, Navratilova M, Schmutzler RK, Ellberg C, Gerdes A-M, Caldes T, Simard J, Olah E, Jakubowska A, Rantala J, Osorio A, Hopper JL, Phillips K-A, Milne RL, Beth Terry M, Noguès C, Engel C, Kast K, Goldgar DE, van Leeuwen FE, Easton DF, Andrieu N, Rookus MA (2021) Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. Am J Obstet Gynecol 225:51.e1-51.e17. https://doi.org/10.1016/j.ajog.2021.01.014
doi: 10.1016/j.ajog.2021.01.014
pubmed: 33493488
Schrijver LH, Mooij TM, Pijpe A, Sonke GS, Mourits MJE, Andrieu N, Antoniou AC, Easton DF, Engel C, Goldgar D, John EM, Kast K, Milne RL, Olsson H, Phillips K-A, Terry MB, Hopper JL, van Leeuwen FE, Rookus MA (2022) Oral contraceptive use in BRCA1 and BRCA2 mutation carriers: absolute cancer risks and benefits. J Natl Cancer Inst 114:540–552. https://doi.org/10.1093/jnci/djac004
doi: 10.1093/jnci/djac004
pubmed: 35048954
pmcid: 9002279
Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, Ghadirian P, Rosen B, Tung N, Kim-Sing C, Foulkes WD, Neuhausen SL, Senter L, Singer CF, Karlan B, Ping S, Narod SA (2013) The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol 130:127–131. https://doi.org/10.1016/j.ygyno.2013.03.027
doi: 10.1016/j.ygyno.2013.03.027
pubmed: 23562522
Segev Y, Rosen B, Lubinski J, Gronwald J, Lynch HT, Moller P, Kim-Sing C, Ghadirian P, Karlan B, Eng C, Gilchrist D, Neuhausen SL, Eisen A, Friedman E, Euhus D, Ping S, Narod SA (2015) Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. Fam Cancer 14:383–391. https://doi.org/10.1007/s10689-015-9798-8
doi: 10.1007/s10689-015-9798-8
pubmed: 25838159
pmcid: 4962606
Sergentanis TN, Diamantaras A-A, Perlepe C, Kanavidis P, Skalkidou A, Petridou ET (2014) IVF and breast cancer: a systematic review and meta-analysis. Hum Reprod Update 20:106–123. https://doi.org/10.1093/humupd/dmt034
doi: 10.1093/humupd/dmt034
pubmed: 23884897
Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, Nathanson KL, Konner JA, Arnold AG, Bogomolniy F, Dao F, Olvera N, Bancroft EK, Goldfrank DJ, Stadler ZK, Robson ME, Brown CL, Leitao MM, Abu-Rustum NR, Aghajanian CA, Blum JL, Neuhausen SL, Garber JE, Daly MB, Isaacs C, Eeles RA, Ganz PA, Barakat RR, Offit K, Domchek SM, Rebbeck TR, Kauff ND (2016) Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol 2:1434–1440. https://doi.org/10.1001/jamaoncol.2016.1820
doi: 10.1001/jamaoncol.2016.1820
pubmed: 27367496
pmcid: 5594920
Siristatidis C, Sergentanis TN, Kanavidis P, Trivella M, Sotiraki M, Mavromatis I, Psaltopoulou T, Skalkidou A, Petridou ET (2013) Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer–a systematic review and meta-analysis. Hum Reprod Update 19:105–123. https://doi.org/10.1093/humupd/dms051
doi: 10.1093/humupd/dms051
pubmed: 23255514
Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E (2016) Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube. Acta Oncol 55:1281–1284. https://doi.org/10.1080/0284186X.2016.1175660
doi: 10.1080/0284186X.2016.1175660
pubmed: 27148621
Sourander L, Rajala T, Räihä I, Mäkinen J, Erkkola R, Helenius H (1998) Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 352:1965–1969. https://doi.org/10.1016/S0140-6736(98)05066-1
doi: 10.1016/S0140-6736(98)05066-1
pubmed: 9872245
Stahlberg C, Pedersen AT, Lynge E, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Ottesen B (2004) Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 109:721–727. https://doi.org/10.1002/ijc.20016
doi: 10.1002/ijc.20016
pubmed: 14999781
Tempfer CB, Hilal Z, Kern P, Juhasz-Boess I, Rezniczek GA (2020) Menopausal hormone therapy and risk of endometrial cancer: a systematic review. Cancers. https://doi.org/10.3390/cancers12082195
doi: 10.3390/cancers12082195
pubmed: 33348855
pmcid: 7766637
Thompson D, Easton DF (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358–1365. https://doi.org/10.1093/jnci/94.18.1358
doi: 10.1093/jnci/94.18.1358
pubmed: 12237281
Tjønneland A, Christensen J, Thomsen BL, Olsen A, Overvad K, Ewertz M, Mellemkjaer L (2004) Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer 100:2328–2337. https://doi.org/10.1002/cncr.20250
doi: 10.1002/cncr.20250
pubmed: 15160335
van Bommel MHD, IntHout J, Veldmate G, Kets CM, de Hullu JA, van Altena AM, Harmsen MG (2023) Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis. Hum Reprod Update 29:197–217. https://doi.org/10.1093/humupd/dmac038
doi: 10.1093/humupd/dmac038
pubmed: 36383189
van den Belt-Dusebout AW, Spaan M, Lambalk CB, Kortman M, Laven JSE, van Santbrink EJP, van der Westerlaken LAJ, Cohlen BJ, Braat DDM, Smeenk JMJ, Land JA, Goddijn M, van Golde RJT, van Rumste MM, Schats R, Józwiak K, Hauptmann M, Rookus MA, Burger CW, van Leeuwen FE (2016) Ovarian stimulation for in vitro fertilization and long-term risk of breast cancer. JAMA 316:300–312. https://doi.org/10.1001/jama.2016.9389
doi: 10.1001/jama.2016.9389
pubmed: 27434442
van der Klift M, de Laet CEDH, McCloskey EV, Johnell O, Kanis JA, Hofman A, Pols HAP (2004) Risk factors for incident vertebral fractures in men and women: the Rotterdam study. J Bone Miner Res 19:1172–1180. https://doi.org/10.1359/JBMR.040215
doi: 10.1359/JBMR.040215
pubmed: 15177001
Vega EM, Egea MA, Mautalen CA (1994) Influence of the menopausal age on the severity of osteoporosis in women with vertebral fractures. Maturitas 19:117–124. https://doi.org/10.1016/0378-5122(94)90061-2
doi: 10.1016/0378-5122(94)90061-2
pubmed: 7968644
Vermeulen RFM, van Beurden M, Korse CM, Kenter GG (2017) Impact of risk-reducing salpingo-oophorectomy in premenopausal women. Climacteric 20:212–221. https://doi.org/10.1080/13697137.2017.1285879
doi: 10.1080/13697137.2017.1285879
pubmed: 28509627
Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345:1243–1249. https://doi.org/10.1056/NEJMoa010534
doi: 10.1056/NEJMoa010534
pubmed: 11680444
Willis DB, Calle EE, Miracle-McMahill HL, Heath CW (1996) Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 7:449–457. https://doi.org/10.1007/BF00052671
doi: 10.1007/BF00052671
pubmed: 8813433
Xia YY, Gronwald J, Karlan B, Lubinski J, McCuaig JM, Brooks J, Moller P, Eisen A, Sun S, Senter L, Bordeleau L, Neuhausen SL, Singer CF, Tung N, Foulkes WD, Sun P, Narod SA, Kotsopoulos J (2022) Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol 164:514–521. https://doi.org/10.1016/j.ygyno.2022.01.014
doi: 10.1016/j.ygyno.2022.01.014
pubmed: 35063280